KAER Biotherapeutics
KAER Biotherapeutics is dedicated to serving patients with respiratory distress by developing innovative aerosolized therapeutic devices such as AeroPulsR and SUPRAER-Clinic. Their mission is to significantly reduce mortality rates in respiratory distress patients through advanced aerosol delivery technology, targeting critical care settings and animal healthcare. They focus on high-concentration aerosol delivery of various therapeutics, including biologics, antibiotics, and surfactants, with a strong emphasis on efficacy, safety, and regulatory compliance.
Industries
Nr. of Employees
small (1-50)
KAER Biotherapeutics
926 S Andreasen Dr., Suite 105, Escondido, California, 92029
Patents
Apparatus and method for generating and concentrating fine particle aerosols
US-10207062-B2
View DetailsTwo-stage apparatus and method for generating and concentrating fine particle aerosols
US-9937303-B1
View Details
Apparatus and method for generating and concentrating fine particle aerosols
US-10207062-B2
View DetailsTwo-stage apparatus and method for generating and concentrating fine particle aerosols
US-9937303-B1
View DetailsProducts
Aqueous aerosol generation and delivery platform (high‑dose, pulsed)
A device platform that produces respirable aqueous aerosols (2–4 µm) with selectable aerosolization rates (~0.5–4 ml/min), supports liquids up to ~50 cP, operates on compressed air/oxygen/heliox, features a clog‑free single‑pass nozzle and supports continuous, periodic or inspiration‑synchronized pulsed delivery for rapid high‑dose treatment.
Solid‑phase dry aerosol generation platform (high output)
A platform that converts liquid drugs into fine respirable dry aerosols (selectable 2–4 µm MMAD) in a single stage, with high dose rates (reported up to ~4 mg/s), capacity to deliver multi‑gram doses quickly (example: up to 2 g in under 10 minutes), no requirement for additional excipients, and control over output humidity.
Clinic‑focused solid‑phase aerosol treatment system
Simplified clinical console for dry aerosol treatment featuring onboard dispenser loading, LCD input of treatment parameters (breaths, inspiration/expiration duration), and single‑button therapy start; designed for use by clinical staff or trained patients.
Aqueous aerosol generation and delivery platform (high‑dose, pulsed)
A device platform that produces respirable aqueous aerosols (2–4 µm) with selectable aerosolization rates (~0.5–4 ml/min), supports liquids up to ~50 cP, operates on compressed air/oxygen/heliox, features a clog‑free single‑pass nozzle and supports continuous, periodic or inspiration‑synchronized pulsed delivery for rapid high‑dose treatment.
Solid‑phase dry aerosol generation platform (high output)
A platform that converts liquid drugs into fine respirable dry aerosols (selectable 2–4 µm MMAD) in a single stage, with high dose rates (reported up to ~4 mg/s), capacity to deliver multi‑gram doses quickly (example: up to 2 g in under 10 minutes), no requirement for additional excipients, and control over output humidity.
Clinic‑focused solid‑phase aerosol treatment system
Simplified clinical console for dry aerosol treatment featuring onboard dispenser loading, LCD input of treatment parameters (breaths, inspiration/expiration duration), and single‑button therapy start; designed for use by clinical staff or trained patients.
Services
Aerosolization of liquids and solids (including proteins, biologics, surfactants, antibiotics, DNA) and measurement/characterization of particle size, concentration and biological activity.
Consultation on processing parameters for aerosolizing agents, including selection of operating gas, flow rates, and plume timing to meet target dosing and safety constraints.
Spray drying of expensive agents on a small scale (reported down to ~200 µL) and formulation preparation for dry aerosol generation.
Assessment and consulting services for inhalation toxicology and safety of aerosolized formulations.
Opportunities for partnering to develop and commercialize aerosolized APIs and device integrations for human and animal healthcare.
Aerosolization of liquids and solids (including proteins, biologics, surfactants, antibiotics, DNA) and measurement/characterization of particle size, concentration and biological activity.
Consultation on processing parameters for aerosolizing agents, including selection of operating gas, flow rates, and plume timing to meet target dosing and safety constraints.
Spray drying of expensive agents on a small scale (reported down to ~200 µL) and formulation preparation for dry aerosol generation.
Assessment and consulting services for inhalation toxicology and safety of aerosolized formulations.
Opportunities for partnering to develop and commercialize aerosolized APIs and device integrations for human and animal healthcare.
Expertise Areas
- Aerosol drug delivery
- Inhaled therapeutics development
- Pulmonary surfactant aerosolization
- Preclinical inhalation toxicology
Key Technologies
- Aqueous aerosol generation (2–4 µm)
- Solid‑phase dry aerosol generation from liquids (2–4 µm)
- Pulsed/inspiration‑timed aerosol delivery
- Heliox/compressed gas‑driven aerosolization
News & Updates
Donovan B. Yeates will present at the BIO 2025 conference in Boston, USA, from June 16-19, 2025.
KAER will present and showcase its latest AeroPulsR technology at the ISAM Congress in Washington DC, USA, from June 22-25, 2025.
Patent Portfolio
KAER holds 22 issued patents and 5 pending patents covering 6 major continents and countries.
Donovan B. Yeates will present at the BIO 2025 conference in Boston, USA, from June 16-19, 2025.
KAER will present and showcase its latest AeroPulsR technology at the ISAM Congress in Washington DC, USA, from June 22-25, 2025.
Patent Portfolio
KAER holds 22 issued patents and 5 pending patents covering 6 major continents and countries.